m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02487)
Name
Rogletimide
Synonyms
ROGLETIMIDE; Pyridoglutethimide; 92788-10-8; 3-PYG; (+-)-Pyridoglutethimide; Racemic-pyridoglutethimide; 2-Ethyl-2-(4-pyridyl)glutarimide; 121840-95-7; 3-Ethyl-3-(4-pyridyl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-ethyl-3-(4-pyridinyl)-; CHEMBL289116; 3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione; 3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione; (+/-) 3-Ethyl-3-(4-pyridinyl)-2,6-piperidinedione; 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione; Rogletimida; Rogletimidum; Rogletimidum [INN-Latin]; Rogletimida [INN-Spanish]
    Click to Show/Hide
Status
Terminated
Structure
Formula
C12H14N2O2
InChI
1S/C12H14N2O2/c1-2-12(9-4-7-13-8-5-9)6-3-10(15)14-11(12)16/h4-5,7-8H,2-3,6H2,1H3,(H,14,15,16)
InChIKey
QXKJWHWUDVQATH-UHFFFAOYSA-N
PubChem CID
56487
TTD Drug ID
D06JUR
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aromatase (CYP19A1) is a therapeutic target for Rogletimide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Rogletimide through regulating the expression of Aromatase (CYP19A1). [1], [2]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer. 1999 Jun;6(2):197-204. doi: 10.1677/erc.0.0060197.